身體認識：文化傳統與醫家──以《黃帝內經素問》為中心論古代思想傳統中的身體觀

International audienc

Effects of Molecular Structures on the Properties of Polyimides and Photopatternable Polyimide/Silica for Optical Waveguide Applications

Produit de vulgarisation scientifiqu

Apprendre à conduire un attelage avec le simulateur interactif coMtactS

International audienc

Mobile phone data for informing public health actions across the COVID-19 pandemic life cycle

The coronavirus 2019-2020 pandemic (COVID-19) poses unprecedented challenges for governments and societies around the world (1). Non-pharmaceutical interventions (NPIs) have proven to be critical for delaying and containing the COVID-19 pandemic (2–6). This includes testing and tracing, bans on large gatherings, non-essential business and school and university closures, international and domestic mobility restrictions and physical isolation, and total lockdowns of regions and countries. Decision-making and evaluation or such interventions during all stages of the pandemic lifecycle require specific, reliable and timely data not only about infections, but also about human behavior, especially mobility and physical co-presence. We argue that mobile phone data, when used properly and carefully, represents a critical arsenal of tools for supporting public health actions across early, middle, and late-stage phases of the COVID-19 pandemic

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events